These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34681729)

  • 1. IAF, QGF, and QDF Peptides Exhibit Cholesterol-Lowering Activity through a Statin-like HMG-CoA Reductase Regulation Mechanism: In Silico and In Vitro Approach.
    Silva M; Philadelpho B; Santos J; Souza V; Souza C; Santiago V; Silva J; Souza C; Azeredo F; Castilho M; Cilli E; Ferreira E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in silico studies of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitory activity of the cowpea Gln-Asp-Phe peptide.
    Silva MBCE; Souza CADC; Philadelpho BO; Cunha MMND; Batista FPR; Silva JRD; Druzian JI; Castilho MS; Cilli EM; Ferreira ES
    Food Chem; 2018 Sep; 259():270-277. PubMed ID: 29680054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural mechanism for statin inhibition of HMG-CoA reductase.
    Istvan ES; Deisenhofer J
    Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
    Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH
    Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Istvan ES
    Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.
    Islam B; Sharma C; Adem A; Aburawi E; Ojha S
    Drug Des Devel Ther; 2015; 9():4943-51. PubMed ID: 26357462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.
    Lin SH; Huang KJ; Weng CF; Shiuan D
    Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-silico HMG-CoA reductase-inhibitory and in-vivo anti-lipidaemic/anticancer effects of carotenoids from Spondias mombin.
    Metibemu DS; Akinloye OA; Akamo AJ; Okoye JO; Omotuyi IO
    J Pharm Pharmacol; 2021 Sep; 73(10):1377-1386. PubMed ID: 34343336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin inhibition of HMG-CoA reductase: a 3-dimensional view.
    Istvan E
    Atheroscler Suppl; 2003 Mar; 4(1):3-8. PubMed ID: 12714031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
    Karthik MV; Satya Deepak MV; Shukla P
    Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new druggable sites in the anti-cholesterol target HMG-CoA reductase by computational alanine scanning mutagenesis.
    Gesto DS; Cerqueira NM; Ramos MJ; Fernandes PA
    J Mol Model; 2014 Apr; 20(4):2178. PubMed ID: 24671303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the principal catalytically important acidic residue of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Wang Y; Darnay BG; Rodwell VW
    J Biol Chem; 1990 Dec; 265(35):21634-41. PubMed ID: 2123872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
    Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
    Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteopedia entry: HMG-CoA reductase.
    Canner D
    Biochem Mol Biol Educ; 2011; 39(1):64. PubMed ID: 21433257
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of an HMG-CoA reductase from Listeria monocytogenes that exhibits dual coenzyme specificity.
    Theivagt AE; Amanti EN; Beresford NJ; Tabernero L; Friesen JA
    Biochemistry; 2006 Dec; 45(48):14397-406. PubMed ID: 17128979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations.
    Son M; Baek A; Sakkiah S; Park C; John S; Lee KW
    PLoS One; 2013; 8(12):e83496. PubMed ID: 24386216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Inhibitors of HMG-CoA Reductase-An Insilico Approach Through Molecular Docking and Simulation Studies.
    Suganya S; Nandagopal B; Anbarasu A
    J Cell Biochem; 2017 Jan; 118(1):52-57. PubMed ID: 27216569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of HMG-CoA reductase inhibitory and antioxidant effects of various hydroxycoumarin derivatives.
    Ozalp L; Danış Ö; Yuce-Dursun B; Demir S; Gündüz C; Ogan A
    Arch Pharm (Weinheim); 2020 Oct; 353(10):e1900378. PubMed ID: 32648617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.
    Holdgate GA; Ward WH; McTaggart F
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):528-31. PubMed ID: 12773150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore Modeling and Binding Affinity of Secondary Metabolites from
    Aulifa DL; Amirah SR; Rahayu D; Megantara S; Muchtaridi M
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.